查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938196

自動化細胞計數市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、應用、最終用途、地區和競爭格局分類，2021-2031年）

Automated Cell Counting Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球自動細胞計數市場預計將從 2025 年的 41.3 億美元成長到 2031 年的 86.8 億美元，複合年成長率達到 13.18%。

這些利用電化學電阻譜和光學影像分析技術對細胞進行定量和活性測定的自動化儀器，正日益取代人工血球計數器。這種成長主要受慢性病發病率上升和生物製藥研究範圍擴大的推動，而生物製藥研究需要精確的細胞分析。例如，美國癌症協會估計，到2024年，美國新增癌症病例將首次超過200萬例，日益成長的癌症負擔推動了藥物研發和臨床診斷領域對高效細胞計數技術的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 41.3億美元
市場規模：2031年 86.8億美元
複合年成長率：2026-2031年 13.18%
成長最快的細分市場 裝置
最大的市場 北美洲

儘管市場有所擴張，但由於高度自動化系統（尤其是採用螢光成像的系統）的高昂購買成本，該市場仍面臨許多障礙。小規模的學術實驗室和發展中地區的實驗室可能難以承擔這些購置成本，從而繼續依賴人工技術。此外，設備維護和專用耗材的持續支出也會對營運預算造成壓力，阻礙其在價格敏感地區的廣泛市場滲透。

市場促進因素

影像分析技術的進步和人工智慧的融合正在顯著提高細胞定量分析的準確性和速度，從而變革全球自動化細胞計數市場。現代系統利用機器學習演算法，比傳統光學技術更能有效地區分活細胞、死細胞和細胞碎片。這種發展最大限度地減少了人為誤差，並確保了不同實驗結果的一致性，這對於高通量篩檢和複雜的生物鑑定至關重要。 LUNA-III 自動化細胞計數器於 2024 年 9 月上市，正是這一趨勢的有力佐證。該產品利用先進的機器學習技術，顯著提升了自動對焦和細胞辨識能力，尤其適用於處理各種工作流程中的細胞團塊。

同時，在細胞研究和再生醫學領域資金投入增加的推動下，生物製藥和生技產業蓬勃發展，市場需求也隨之成長。隨著企業從研發階段邁向細胞療法的商業化生產，對檢驗且符合規範的細胞計數解決方案的需求至關重要，以確保產品的安全性和均一性。根據再生醫學聯盟（Alliance for Regenerative Medicine）統計，截至2025年1月，全球細胞和基因治療研發公司數量年增6%，顯示此類儀器的基本客群正在不斷擴大。這一行業擴張也與臨床進展相吻合。國際細胞和基因治療學會（ISCT）在2025年1月報告稱，2024年有七種新型細胞和基因治療產品獲得美國食品藥品監督管理局（FDA）核准，證實了其商業性可行性，從而推動了精密分析工具的應用。

市場挑戰

自動化細胞計數器的高昂購置成本是限制市場成長的一大障礙。先進的系統，尤其是那些配備螢光檢測功能的系統，需要大量的資本投入，這往往超出了發展中地區小規模學術和研究實驗室的購買力。這種經濟障礙迫使許多機構繼續依賴手動血球計數器，而手動血球計數器的通量較低且容易出現人為誤差。因此，在那些預算優先用於購買必要試劑而非設備升級的成本敏感市場，自動化解決方案的市場滲透率受到限制，從而影響了其整體普及率。

此外，包括持續維護和專用耗材在內的總擁有成本 (TCO) 也給營運預算帶來了額外壓力。如果科研經費預計不會增加，這種財務負擔會更加沉重。例如，根據美國科學促進會 (AAAS) 的數據，美國國立衛生研究院 (NIH) 2024 會計年度的聯邦預算約為 471 億美元，這項固定撥款實際上降低了購買力，並因通貨膨脹而難以購買新的實驗室設備。這些財務限制迫使實驗室推遲實施新的自動化系統，直接阻礙了全球市場的收入成長。

市場趨勢

隨著企業從研發階段轉向大規模商業化生產，開發用於細胞和基因治療生產的專用解決方案已成為設備製造商的首要任務。這一趨勢重新激發了對專用合規硬體的資本投資，以管理複雜的生產流程。與通用實驗室設備相比，隨著生物技術產業財務壓力的緩解和生產能力的提升，這些專用系統正迅速普及。根據ChemoMetec於2024年9月發布的“2024/2025第一季報告”，該公司設備銷售額年增61%。這一成長直接歸功於細胞和基因治療公司獲得的新資本注入，從而加強了其基礎設施建設。

同時，單細胞定序工作流程的廣泛應用正在推動市場成長。此應用需要嚴格的上游工程品管。在單細胞RNA定序（scRNA-seq）中，準確評估細胞活力和濃度至關重要，以避免因試劑和定序運行成本高而導致的代價高昂的實驗失敗。這種高價值的工作流程持續推動著對能夠在下游處理前準確檢驗樣本品質的自動化計數器的需求。例如，10x Genomics在2025年2月發布的「2024年第四季及全年財報」中公佈了6.108億美元的全年營收，凸顯了依賴精確細胞計數的大規模單細胞研究活動的重要性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球自動化細胞計數市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（設備、耗材及配件）
    • 依應用領域（血液分析、幹細胞研究、細胞株開發等）
    • 按最終用戶分類（製藥和生物技術公司、醫院和診斷檢查室、研究和學術機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美自動化細胞數市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲自動化細胞計數市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區自動化細胞計數市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲自動化細胞計數市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲自動化細胞計數市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球自動化細胞計數市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Merck KgaA
  • Countstar, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Chemometec A/S
  • Olympus Corporation
  • Sysmex Corporation
  • Agilent Technologies, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27620

The Global Automated Cell Counting Market is projected to expand from USD 4.13 Billion in 2025 to USD 8.68 Billion by 2031, achieving a compound annual growth rate of 13.18%. These automated instruments, which utilize electrical impedance or optical image analysis to quantify cells and determine viability, are increasingly superseding manual hemocytometers. A primary catalyst for this growth is the rising prevalence of chronic diseases alongside the broadening scope of biopharmaceutical research that necessitates precise cellular analysis. For instance, the American Cancer Society estimates that new cancer diagnoses in the United States will surpass 2 million for the first time in 2024, a burden that intensifies the need for efficient cell counting technologies within drug discovery and clinical diagnostics.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.13 Billion
Market Size 2031USD 8.68 Billion
CAGR 2026-203113.18%
Fastest Growing SegmentInstruments
Largest MarketNorth America

Despite this expansion, the market faces a substantial hurdle due to the high purchase price of advanced automated systems, especially those employing fluorescence imaging. Small-scale academic laboratories and research entities in developing regions often find these capital costs prohibitive, resulting in a persistent dependence on manual techniques. Moreover, the recurring expenses related to instrument maintenance and proprietary consumables can burden operational budgets, a factor that potentially hinders widespread market penetration in price-sensitive regions.

Market Driver

Technological progress in image analysis and the integration of artificial intelligence are transforming the Global Automated Cell Counting Market by markedly enhancing the precision and speed of cellular quantification. Contemporary systems increasingly leverage machine learning algorithms to differentiate between viable cells, dead cells, and debris with a level of accuracy that outperforms traditional optical techniques. This evolution minimizes human error and ensures consistent results across varied experiments, which is essential for high-throughput screening and complex biological assays. As evidence of this trend, Logos Biosystems introduced the LUNA-III automated cell counter in September 2024, deploying advanced machine learning to improve autofocusing and cell recognition, specifically to manage aggregated cells in diverse workflows.

Simultaneously, the growth of the biopharmaceutical and biotechnology industries, fueled by increased funding for cell-based research and regenerative medicine, is driving market demand. As companies progress from research phases to commercial-scale manufacturing of cell therapies, the requirement for validated, regulatory-compliant cell counting solutions becomes critical for ensuring product safety and uniformity. According to the Alliance for Regenerative Medicine, the number of cell and gene therapy developers globally increased by 6% over the past year as of January 2025, highlighting a growing customer base for these instruments. This industrial expansion aligns with clinical progress; the International Society for Cell & Gene Therapy reported in January 2025 that seven new cell and gene therapy products received FDA approval in 2024, confirming the commercial viability that spurs the adoption of precise analytical tools.

Market Challenge

The substantial acquisition costs linked to automated cell counting instruments represent a significant impediment to market growth. Sophisticated systems, especially those capable of fluorescence detection, necessitate a level of capital expenditure that often outstrips the purchasing power of smaller academic laboratories and research institutions in developing areas. This financial hurdle compels many facilities to depend on manual hemocytometers, despite their lower throughput and increased susceptibility to human error. As a result, the market faces difficulties penetrating cost-conscious sectors where budget priorities favor essential reagents over equipment upgrades, thereby restricting the overall rate of adoption for automated solutions.

Additionally, the total cost of ownership, encompassing continuous maintenance and proprietary consumables, exerts further pressure on operational budgets. This economic strain is exacerbated when research funding fails to grow. For example, the American Association for the Advancement of Science noted that the 2024 federal budget for the National Institutes of Health was finalized at roughly 47.1 billion dollars, a flat funding trajectory that effectively diminished purchasing power for new laboratory instrumentation due to inflation. Such fiscal limitations force laboratories to postpone the acquisition of new automated systems, directly hindering revenue expansion within the global market.

Market Trends

The development of specialized solutions for cell and gene therapy manufacturing has emerged as a central priority for instrument manufacturers, spurred by the sector's transition from research to large-scale commercial production. This trend involves a renewed investment in capital expenditure for dedicated, regulatory-compliant hardware designed to manage complex manufacturing workflows. In contrast to general-purpose laboratory equipment, these specialized systems are experiencing rapid adoption as financial pressures within the biotech industry alleviate and manufacturing capabilities grow. According to ChemoMetec's 'Interim Report for Q1 2024/25' from September 2024, the company observed a 61% rise in instrument sales year-over-year, a growth directly linked to the fresh capital infused into cell and gene therapy companies for infrastructure enhancements.

Concurrently, the proliferation of single-cell sequencing workflows is driving market momentum, as this application demands rigorously strict upstream quality control. In single-cell RNA sequencing (scRNA-seq), the substantial costs associated with reagents and sequencing runs make the precise evaluation of cell viability and concentration essential to avoid costly experimental failures. This high-value workflow has generated a persistent demand for automated counters capable of accurately validating sample quality prior to downstream processing. Highlighting the magnitude of this application, 10x Genomics reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 that full-year revenue reached 610.8 million dollars, emphasizing the considerable volume of single-cell research activities dependent on accurate cellular enumeration.

Key Market Players

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Merck KgaA
  • Countstar, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Chemometec A/S
  • Olympus Corporation
  • Sysmex Corporation
  • Agilent Technologies, Inc.

Report Scope

In this report, the Global Automated Cell Counting Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Automated Cell Counting Market, By Product

  • Instruments
  • Consumables & Accessories

Automated Cell Counting Market, By Application

  • Blood Analysis
  • Stem Cell Research
  • Cell Line development
  • Others

Automated Cell Counting Market, By End Use

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Diagnostic laboratories
  • Research & Academic Institutes
  • Others

Automated Cell Counting Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Automated Cell Counting Market.

Available Customizations:

Global Automated Cell Counting Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Automated Cell Counting Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Consumables & Accessories)
    • 5.2.2. By Application (Blood Analysis, Stem Cell Research, Cell Line development, Others)
    • 5.2.3. By End Use (Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic laboratories, Research & Academic Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Automated Cell Counting Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Automated Cell Counting Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada Automated Cell Counting Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico Automated Cell Counting Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End Use

7. Europe Automated Cell Counting Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Automated Cell Counting Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End Use
    • 7.3.2. France Automated Cell Counting Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Automated Cell Counting Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Automated Cell Counting Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Automated Cell Counting Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End Use

8. Asia Pacific Automated Cell Counting Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Automated Cell Counting Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Automated Cell Counting Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan Automated Cell Counting Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea Automated Cell Counting Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Automated Cell Counting Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End Use

9. Middle East & Africa Automated Cell Counting Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Automated Cell Counting Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE Automated Cell Counting Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa Automated Cell Counting Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End Use

10. South America Automated Cell Counting Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Automated Cell Counting Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia Automated Cell Counting Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina Automated Cell Counting Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Automated Cell Counting Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Danaher Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. Merck KgaA
  • 15.4. Countstar, Inc.
  • 15.5. Bio-Rad Laboratories, Inc.
  • 15.6. F. Hoffmann-La Roche Ltd
  • 15.7. Chemometec A/S
  • 15.8. Olympus Corporation
  • 15.9. Sysmex Corporation
  • 15.10. Agilent Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer